NASDAQ: XLOXilio Therapeutics Inc Stock
$0.81-0.01 (-1.22%)
Updated Oct 29, 2025
XLO Price
$0.81
Fair Value Price
N/A
Market Cap
$41.98M
52 Week Low
$0.62
52 Week High
$1.70
P/E
-1.09x
P/B
5.94x
P/S
4.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.00M
Earnings
-$56.22M
Gross Margin
100%
Operating Margin
-374.79%
Profit Margin
-374.8%
Debt to Equity
17.93
Operating Cash Flow
-$13M
Beta
0.93
Next Earnings
Nov 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
XLO Overview
Xilio Therapeutics Incorporated is a biotech company that develops immunotherapies for cancer patients. Its inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XLO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XLO
Ranked#194 of 488
Ranked#194 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.17 | A | |
| $12.22 | A | |
| $7.19 | A |
Be the first to know about important XLO news, forecast changes, insider trades & much more!
XLO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XLO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XLO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XLO is poor value based on its book value relative to its share price (5.94x), compared to the US Biotechnology industry average (4.96x)
P/B vs Industry Valuation
XLO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XLO due diligence checks available for Premium users.
Valuation
XLO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.09x
Industry
-90.6x
Market
41.57x
XLO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.94x
Industry
4.96x
XLO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XLO's financial health
Profit margin
Revenue
$8.1M
Net Income
-$15.8M
Profit Margin
-196%
XLO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XLO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$133.8M
Liabilities
$126.7M
Debt to equity
17.93
XLO's short-term assets ($123.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XLO's short-term assets ($123.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XLO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.5M
Investing
-$401.0k
Financing
$47.4M
XLO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XLO vs Biotech Stocks
Xilio Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.